Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Application Of Lecanemab (BAN2401) For Early Alzheimer’s Disease Under The Accelerated Approval Pathway
TOKYO and CAMBRIDGE, Mass., Sept. 27, 2021 /PRNewswire/ -- Eisai Company, Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ...
